Lumin Health opens first location outside Massachusetts in Bethesda

By AI, Created 8:45 PM UTC, May 20, 2026, /AGP/ – Lumin Health has opened a new Bethesda, Maryland, site, marking its first location outside Massachusetts and expanding access to medically supervised ketamine treatment and FDA-approved Spravato in the D.C. area. The clinic accepts Medicare and most private insurance plans and comes as the company reports strong 2025 treatment volumes and outcomes across its Boston-area sites.

Why it matters: - Lumin Health is extending an insurance-accessible model of interventional depression care into the Washington, D.C. metro area. - The Bethesda opening gives patients outside Massachusetts access to medically supervised ketamine treatment and FDA-approved esketamine, also known as SPRAVATO®. - The move matters for patients with depression who have not improved after multiple treatments and need another clinically supervised option.

What happened: - Lumin Health opened a new location at 4825 Bethesda Avenue, Suite 200, in Bethesda, Maryland. - The Bethesda site is Lumin Health’s first location outside Massachusetts. - The practice describes the site as an extension of its psychiatrist-led, medically supervised interventional behavioral health care model. - The opening was featured on WUSA9. - More information is available at the Bethesda site.

The details: - Lumin Health’s care model is built on FDA-approved esketamine (SPRAVATO®) and evidence-based, clinician-led ketamine protocols. - Lumin Health says the Bethesda clinic accepts Medicare and most private insurance plans. - Dr. Benjamin Yudkoff, founder and chief medical officer, said the Bethesda launch brings a trusted, medically supervised model to a new patient population. - Yudkoff said the company also wants to partner with community providers in the region to reach patients who might otherwise keep struggling. - In 2025, Lumin Health delivered more than 12,300 treatments across its Boston-area facilities. - Among patients treated in 2025, 70% showed clinically meaningful improvement in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale. - Among patients with moderate-to-severe depression, 78% improved. - Lumin Health operates four locations in the Boston area and one in Bethesda.

Between the lines: - The Bethesda expansion suggests Lumin Health is betting that demand for interventional depression care extends beyond its home market. - The company is positioning insurance coverage as part of the access story, not just the treatment itself. - The 2025 outcomes data gives the expansion a performance backdrop, though the results come from the company’s own patient population.

What’s next: - Lumin Health will use the Bethesda location to serve patients across the D.C. metro area. - The company is likely to lean on community-provider partnerships to build referrals and expand reach. - Additional patient volume and outcome data from Bethesda will show how quickly the model scales outside Massachusetts.

The bottom line: - Lumin Health is taking its depression-treatment model to a new region, backed by insurance acceptance and in-house outcomes data.